Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer
May 9th 2022Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.
Read More
FDA Approves Enhertu for Use in Metastatic Breast Cancer
May 5th 2022This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.
Read More
Contributor: Helping Women of Color Achieve a Healthier Future
April 27th 2022To achieve health equity, experts from CVS Health discuss why we must invest in programs that improve access to health care for historically marginalized communities, address social determinants, boost health education, increase representation in all levels of health care delivery, widen access to clinical trial research, and more.
Read More
Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography
April 20th 2022This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.
Read More
Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL
April 13th 2022This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.
Read More
Mixed QOL Findings Following Treatment Highlight Need for BC Support Services
April 9th 2022This subanalysis of data from the ECOG-ACRIN E5103 trial evaluated longer-term quality of life (QOL) at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer (BC) who have completed active treatment.
Read More
CDK4/6 Inhibitors, SERDs, and More in NCCN Talk on Breast Cancer Updates
April 1st 2022NCCN guidelines are no longer “a group of monotherapy choices,” but selections that feature partners for endocrine therapy, highlighted William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Read More
MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
March 23rd 2022This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Read More
Considerations to Increase Rates of Breast Cancer Screening Across Populations
Authors from the Community Oncology Alliance and Avalere Health present data that show breast cancer screening rates recovered more slowly among some racial/ethnic groups following on the onset of the COVID-19 pandemic.
Read More
Dr Gregory Vidal: Some Populations Continue to Face Barriers to Care Despite Virtual Options
March 13th 2022Minority, low-income, and elderly patients faced greater barriers to care even when it went virtual during the pandemic, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Watch
A DCIS Diagnosis Introduces Physical, Emotional Uncertainty for Many Women
March 10th 2022This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up
Read More
Dr Gregory Vidal Highlights RPM Technologies for His Patients With Breast Cancer
March 6th 2022During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring (RPM) to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Watch
Possibility of Breast Cancer Overdiagnosis Should Inform Mammography Decisions
February 28th 2022This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.
Read More
Dr Funmi Olopade Describes Advancements in BRCA Gene Testing
February 20th 2022Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains advancements in BRCA testing and how genetic testing has become standard of care.
Watch
Dr Kenneth Cohen: Low-Value Care Exists Across the Health Care System
February 15th 2022Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, discusses areas where low-value care is more prevalent and the shift to high-value care.
Watch
mRNA COVID-19 Vaccines Safe Among Patients With Cancer History
February 7th 2022A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.
Read More
Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer
February 2nd 2022Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Read More
Persistent Care Variations Uncovered in New Breast Cancer Study
January 27th 2022This new analysis among patients with stage I to III breast cancer investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy initiation, and endocrine therapy continuation.
Read More